Study title:
Assessment of the Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIMâ„¢), Administered at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants Included in Two Study Groups Receiving the Hepatitis B Monovalent Vaccine Either at 0, 6, and 14 Weeks
of Age or at 6, 10, and 14 Weeks of Age.
Type of medicine: Non-centrally authorised vaccines
|
Therapeutic area: Virus Diseases
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Vaccine, Adsorbed and Haemophilus influenzae type b conjugate vaccine |
ATC code: |
Document link:
|
Document date: 2011-09-16
|
Study number: E2I29 |
EudraCT number:
|
Scope of study: CLINICAL |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|